Exploración PET-CT con FDG
Imágenes médicas metabólicas de todo el cuerpo que nos ayudan a estadificar y monitorear cánceres agresivos de vejiga, riñón, testículo y próstata metastásico cuando las respuestas precisas son importantes.
Educational content only. All imaging orders are personalized after review by your Advanced Urology physician.
¿Qué es una PET-CT con FDG?
An FDG PET-CT scan uses a radioactive glucose analog — fluorodeoxyglucose (FDG) — to highlight cells with accelerated metabolism. Cancer cells consume glucose rapidly, so they often light up brightly on PET images. We combine that functional data with a CT scan to pinpoint exactly where those hot spots are located.
This technology is especially helpful for aggressive or metastatic urologic cancers where conventional imaging may miss subtle disease.
Cuándo recomendamos PET-CT con FDG
Indicaciones urológicas comunes
- High-grade bladder cancer staging and surveillance.
- Renal cell carcinoma with suspected metastatic spread.
- Testicular cancer restaging when tumor markers rise.
- PSMA-negative prostate cancers or neuroendocrine variants.
- Clarifying indeterminate lesions seen on CT or MRI.
Qué añade FDG PET-CT
- Detects hidden nodal, bone, or visceral metastases.
- Assesses treatment response after immunotherapy or chemotherapy.
- Helps distinguish scar tissue from active tumor.
- Guides biopsy to the most metabolically active site.
Cómo funciona el escaneo
Captación del trazador
You receive an IV injection of FDG. After about 60 minutes of quiet rest (no speaking, minimal movement), the tracer distributes through your body. Cancer cells trap the glucose analogue, making them glow on the PET images.
Fusión PET + TC
The scanner first acquires a low-dose CT for anatomy, followed by PET imaging from skull base to mid-thigh (or head-to-toe when needed). We fuse the datasets to create color overlays that show metabolic activity against high-resolution anatomy.
FDG frente a PSMA PET-CT
| Feature | FDG PET-CT | PSMA PET-CT |
|---|---|---|
| Tracer Target | Glucose uptake (cell metabolism) | Prostate-specific membrane antigen receptors |
| Best For | High-grade bladder, kidney, testicular, sarcomatoid, and aggressive prostate variants | Most prostate cancers, especially biochemical recurrence at low PSA |
| Limitations | Physiologic uptake in brain, bowel, urinary tract can obscure lesions | Some aggressive variants lose PSMA expression |
| Insurance Coverage | Broad coverage for oncologic indications | Rapidly expanding coverage; prior auth required |
Preparándose para su escaneo
24 horas antes
- Follow a low-carbohydrate, high-protein diet; avoid sugary drinks and alcohol.
- Avoid strenuous exercise to prevent muscle uptake.
- Hydrate well with water; stop eating 6 hours before arrival.
Día de la exploración
- Take routine medications unless instructed otherwise (diabetics receive special guidance).
- Wear warm, comfortable clothing without metal.
- Bring recent labs, imaging, and a list of medications.
- Plan to be at the imaging center for about 2.5 hours.
Qué esperar
Durante su visita
- Check in, review your clinical history, and place an IV line.
- Receive the FDG injection, then relax in a quiet room for uptake.
- Empty your bladder before imaging to reduce pelvic artifact.
- Lie still on the scanner table for 20–30 minutes as PET-CT images are acquired.
Después del escaneo
- Drink plenty of fluids to flush tracer through the kidneys and bladder.
- You can resume normal activities immediately.
- Avoid close contact with pregnant individuals or infants for 6 hours.
- Results are interpreted the same day and forwarded to your physician.
Interpretación de los resultados
Revisión multidisciplinaria
Advanced Urology physicians partner with fellowship-trained nuclear radiologists. We integrate the PET-CT findings with pathology, tumor markers, genomic testing, and prior imaging to tailor your care plan.
- Localized uptake may prompt targeted surgery or radiation.
- Oligometastatic disease opens options for stereotactic radiation or metastasis-directed therapy.
- Widespread uptake guides systemic therapy, clinical trials, or palliative strategies.
Riesgos potenciales
- Inflammation, recent surgery, or infection can produce false positives.
- Small lesions under 5 mm may not accumulate enough tracer.
- High blood sugar competes with FDG; we reschedule if glucose is uncontrolled.
Por qué Urología Avanzada
Preguntas frecuentes
¿Es segura la PET-CT con FDG?
Yes. The tracer leaves your body quickly, and the overall radiation dose is comparable to a diagnostic CT. Side effects are rare.
¿El seguro cubrirá la exploración?
Most insurers, including Medicare, cover FDG PET-CT for approved oncologic indications. Our team secures prior authorization before scheduling.
¿Qué tan rápido obtendré resultados?
We typically review and communicate results within one business day, often sooner for urgent cases.
¿Puede la FDG PET-CT sustituir a la biopsia?
It guides biopsy sites but rarely replaces tissue diagnosis. We use it alongside pathology to confirm the exact cancer type.
Próximos pasos
If you have a new cancer diagnosis or need clarification after treatment, our imaging specialists partner with your urologist to determine whether FDG PET-CT is the right next step.